ADDITIONAL SAFETY RESULTS OF HANNAH: A PHASE III RANDOMISED, OPEN-LABEL, INTERNATIONAL STUDY OF THE SUBCUTANEOUS FORMULATION OF TRASTUZUMAB (H) IN HER2-POSITIVE EARLY BREAST CANCER PATIENTS

被引：0

作者：

Jackisch, C. ^{[1
]}

Dank, M. ^{[2
]}

Frasci, G. ^{[3
]}

Park, K. H. ^{[4
]}

Lopez, R. I. ^{[5
]}

Johnston, M. ^{[6
]}

Heinzmann, D. ^{[7
]}

Weber, H. ^{[7
]}

Ismael, G. ^{[8
]}

机构：

[1] Klinikum Offenbach GmbH, Dept Obstet & Gynecol, Offenbach, Germany

[2] Semmelweis Egyet, Radiol & Onkoterapias Klin, Budapest, Hungary

[3] Natl Tumor Inst, Div Med Oncol A, Naples, Italy

[4] Korea Univ, Anam Hosp, Dept Internal Med, Seoul, South Korea

[5] Natl Oncol Inst, Dept Med Oncol, Panama City, Panama

[6] Genentech Inc, San Francisco, CA 94080 USA

[7] F Hoffmann La Roche & Co Ltd, Clin Sci, CH-4002 Basel, Switzerland

[8] Fundat Amaral CarvalhoHosp Jau, Jau, Brazil

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：102 / 103

页数：2